Alternatively, various plant-derived bioactive compounds may directly avert NAFLD and hepatic steatosis by lessening de novo lipogenesis via the direct downregulation of sterol regulatory element-binding protein 1c (SREBP-1c), increasing FA oxidation through upregulating PPAR receptor and improving insulin sensitivity, and decreasing intestinal lipid absorption. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.